Trial intelligence / Profile preview

Iron Oligosaccharide (Monofer) in CHF Patients With Iron Deficiency Anaemia Requiring Parenteral Iron

2007-000764-25Phase 3Completed

Sponsor
Pharmacosmos
Start
Mar 2007
Modality
Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Countries
1
01

Overview

Phase 3, open-label, single-arm trial of ferric derisomaltose in iron deficiency anemia (IDA) and chronic heart failure (CHF), sponsored by Pharmacosmos. Primary endpoint: Safety of Monofer in CHF patients. Started Mar 2007; status: completed.

02

Drugs

ferric derisomaltose
03

Conditions

iron deficiency anemia (IDA)chronic heart failure (CHF)

Beyond the preview

Go deeper on 2007-000764-25.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2007-000764-25.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call